2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter‐defibrillator programming and testing

Wilkoff, Bruce L.; Fauchier, Laurent; Stiles, MBCHB Martin K.; Morillo, Carlos A.; Al‐Khatib, Sana M.; Almendral, Jesœs; Aguinaga, Luis; Berger, Ronald D.; Cuesta, Alejandro; Daubert, James P.; Dubner, Sérgio; Ellenbogen, Kenneth A.; Estes, N.A. Mark; Fenelon, Guilherme; García, Fermin C.; Gasparini, Maurizio; Haines, David E.; Healey, Jeff S.; Hurtwitz, Jodie L.; Keegan, Roberto; Kolb, Christof; Kuck, Karl‐Heinz; Marinskis, Germanas; Filho, Martino Martinelli; McGuire, MBBS Mark; Molina, L; Okumura, Ken; Proclemer, Alessandro; Russo, Andrea M.; Singh, Jagmeet P.; Swerdlow, Charles D.; Teo, MBBS Wee Siong; Uribe, William; Viskin, Sami; Wang, Chun‐Chieh; Zhang, Shu

doi:10.1016/j.joa.2015.12.001

Cited by 41 publications

(15 citation statements)

References 218 publications

(252 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although ICD shocks could terminate those arrhythmias immediately, they would result in both physical and psychological damages and even increase the mortality and hospitalization as proved in some previous studies 2, 3, 4…”

Section: Introductionmentioning

confidence: 91%

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

Fang

Yang

et al. 2017

Journal of Arrhythmia

View full text Add to dashboard Cite

IntroductionVentricular tachycardia (VT) acceleration due to antitachycardia pacing (ATP) therapy could be often observed in patients with implantable cardioverter defibrillator (ICD), which usually results in additional shock. However, few studies focused on the risk factors for VT acceleration caused by ATP therapy. The purpose of this study was to investigate risk factors for VT acceleration due to ATP delivery.MethodsWe retrospectively reviewed 1056 ATP episodes in 33 patients with structural heart diseases, of whom clinical characteristics and episodes details were evaluated.ResultsAt individual patient level, number of VT morphologies recorded in electrograms during follow‐up was a risk factor with cutoff point of 1 (AUC 0.79, sensitivity 72.7%, specificity 77.3%, P < .001) to predict ATP acceleration (OR 3.50, P = .008). From episode‐based analysis, VT cycle length (VTCL) and mean variation in VTCL were risk factors to predict ATP acceleration (OR 0.98, P < 0.001 vs OR 1.06, P < .001, respectively), with cutoff points of 347 ms (AUC 0.67, sensitivity 82.5%, specificity 47.6%, P < .001) and 7.3 ms (AUC 0.66, sensitivity 77.5%, specificity 56.7%, P < .001), respectively. In addition, VTs with cycle length less than 347 ms were more likely to be accelerated by burst stimulation with more pulse numbers (OR 3.31, P < .001).ConclusionsNumber of VT morphologies, VTCL, and mean variation in VTCL are risk factors predicting ATP acceleration. Burst stimulation with less pulse numbers should be performed in VTs with cycle length less than 347 ms.

show abstract

Section: Introductionmentioning

confidence: 91%

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

Fang

Yang

et al. 2017

Journal of Arrhythmia

View full text Add to dashboard Cite

show abstract

“…The parameters will otherwise be programmed according to the manufacturer specific guidelines as per the 2015 Consensus Statement on Optimal ICD Programming and Testing. 21 The EP study is performed using a single extrastimulus protocol as per the standard non-invasive physiological stimulation function of ICDs from all manufacturers and will be performed through the device immediately post implantation.…”

Section: Baseline Assessmentmentioning

confidence: 99%

“…The parameters will otherwise be programmed according to the manufacturer specific guidelines as per the 2015 Consensus Statement on Optimal ICD Programming and Testing. 21 …”

Section: Study Planmentioning

confidence: 99%

Rationale and study design of the MINERVA study: Multicentre Investigation of Novel Electrocardiogram Risk markers in Ventricular Arrhythmia prediction—UK multicentre collaboration

Mistry

Newton

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionThe purpose of this study is to assess the ability of two new ECG markers (Regional Repolarisation Instability Index (R2I2) and Peak Electrical Restitution Slope) to predict sudden cardiac death (SCD) or ventricular arrhythmia (VA) events in patients with ischaemic cardiomyopathy undergoing implantation of an implantable cardioverter defibrillator for primary prevention indication.Methods and analysisMulticentre Investigation of Novel Electrocardiogram Risk markers in Ventricular Arrhythmia prediction is a prospective, open label, single blinded, multicentre observational study to establish the efficacy of two ECG biomarkers in predicting VA risk. 440 participants with ischaemic cardiomyopathy undergoing routine first time implantable cardioverter-defibrillator (ICD) implantation for primary prevention indication are currently being recruited. An electrophysiological (EP) study is performed using a non-invasive programmed electrical stimulation protocol via the implanted device. All participants will undergo the EP study hence no randomisation is required. Participants will be followed up over a minimum of 18 months and up to 3 years. The first patient was recruited in August 2016 and the study will be completed at the final participant follow-up visit. The primary endpoint is ventricular fibrillation or sustained ventricular tachycardia >200 beats/min as recorded by the ICD. The secondary endpoint is SCD. Analysis of the ECG data obtained during the EP study will be performed by the core lab where blinding of patient health status and endpoints will be maintained.Ethics and disseminationEthical approval has been granted by Research Ethics Committees Northern Ireland (reference no. 16/NI/0069). The results will inform the design of a definitive Randomised Controlled Trial (RCT). Dissemination will include peer reviewed journal articles reporting the qualitative and quantitative results, as well as presentations at conferences and lay summaries.Trial registration numberNCT03022487.

show abstract

“…Careful attention to ICD programming is critical to avoid inappropriate shocks for atrial arrhythmias. Given the efficacy of anti-tachycardia pacing in termination of rapid monomorphic VT, ATP should be programmed to deliver therapy for arrhythmias above 200 bpm [39]. Since many episodes of VT terminate spontaneously, extending the duration for arrhythmia detection is useful in all patients.…”

Section: Prevention Of Recurrent Scamentioning

confidence: 99%

Electrophysiologic Considerations After Sudden Cardiac Arrest

Suryanarayana

Garza

Klewer

et al. 2018

CCR

View full text Add to dashboard Cite

show abstract

2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter‐defibrillator programming and testing

Cited by 41 publications

References 218 publications

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes

Rationale and study design of the MINERVA study: Multicentre Investigation of Novel Electrocardiogram Risk markers in Ventricular Arrhythmia prediction—UK multicentre collaboration

Electrophysiologic Considerations After Sudden Cardiac Arrest

Contact Info

Product

Resources

About